| 摘要 |
The present invention relates to the use of c-Abl-, PDGF-R-, c-kit-, or ARG-tyrosine kinase inhibitors, or pharmaceutically acceptable salts thereof, for the treatment, amelioration, and diagnosis of disorders associated with aberrant expression of adipocyte-specific peptide hormone in a patient, e.g., metabolic disorders, e.g., type I diabetes or type II diabetes, and for the manufacture of pharmaceutical compositions for the treatment, amelioration, and diagnosis of disorders associated with aberrant expression of adipocyte-specific peptide hormone in a patient. Examples of c-Abl-, PDGF-R-, c-kit-, or ARG-tyrosine kinase inhibitors include Compound I and Compound II, and pharmaceutically acceptable salts thereof. The ability of the c-Abl-, PDGF-R-, c-kit-, or ARG-tyrosine kinase inhibitors, or pharmaceutically acceptable salts thereof, to treat metabolic disorders is based at least in part on their ability to bind adipocyte-specific peptide hormones such as adiponectin. |
